Clinical Trials Logo

PLASMODIUM FALCIPARUM MALARIA clinical trials

View clinical trials related to PLASMODIUM FALCIPARUM MALARIA.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT02543086 Terminated - Clinical trials for Plasmodium Falciparum Malaria

Effectiveness of KAE609 in Reducing Asexual & Sexual Blood-stage P.Falciparum Infection & Infectivity to Mosquitos

Start date: July 2015
Phase: Phase 1
Study type: Interventional

This is a single-center open label study conducted in multiple sequential cohorts using Induced Blood Stage Malaria infection in healthy volunteers to characterize the effectiveness of KAE609 against sexual and asexual blood stage forms of Plasmodium falciparum. This study is divided in 2 parts (Part A and part B). A total of 8 healthy volunteers per cohort will be enrolled. Based on the results of Part A, Part B will be undertaken to evaluate the effect of KAE609 following pretreatment with Piperaquine on sexual stage/gametocytemia and its activity as an inhibitor of onward transmission to mosquito vectors using experimental mosquito feeding assays.

NCT ID: NCT00304980 Terminated - Clinical trials for Plasmodium Falciparum Malaria

Comparative Evaluation of the Safety and the Efficacy of 2 Antimalarials Depending on HIV Status

Start date: March 2003
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the safety and efficacy of sulfadoxine-pyrimethamine (SP) versus artemether-lumefantrine (Coartem) when administered to HIV+ and HIV- patients with uncomplicated P. falciparum malaria. Patients will be randomised to one of the 2 treatment and followed up (until day 14 actively) for 45 days.

NCT ID: NCT00133393 Terminated - Clinical trials for Plasmodium Falciparum Malaria

Pentoxifylline in Children With Malaria

Start date: January 2002
Phase: Phase 2
Study type: Interventional

The primary objectives of this study is to identify a safe, tolerable dose of pentoxifylline in children with cerebral malaria and to establish an acceptable pentoxifylline dosage regimen for use in multi center Phase II and Phase III studies.